Emtricitabine: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Emtricitabine''' ('''FTC'''), with trade name '''Emtriva''' (formerly '''Coviracil'''), is a [[nucleoside]] [[reverse transcriptase inhibitor]] (NRTI) for the treatment of [[HIV]] infection in adults and children. | |||
Emtricitabine is also marketed in a fixed-dose combination with [[tenofovir]] (Viread) under the brand name '''Truvada'''. A fixed-dose triple combination of emtricitabine, tenofovir and [[efavirenz]] (Sustiva, marketed by [[Bristol-Myers Squibb]]) was approved by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) on July 12, 2006 under the brand name '''Atripla'''. | |||
Emtricitabine makes up one fourth of the [[Stribild|Quad pill]] (brand name: '''Stribild'''). | |||
==Category== | ==Category== | ||
| Line 25: | Line 31: | ||
'''| [[Emtricitabine how supplied|How Supplied]]''' | '''| [[Emtricitabine how supplied|How Supplied]]''' | ||
'''| [[Emtricitabine labels and packages|Labels and Packages]]''' | '''| [[Emtricitabine labels and packages|Labels and Packages]]''' | ||
==Historical Perspective== | |||
Emtricitabine was discovered by Dr. [[Dennis C. Liotta]], Dr. [[Raymond F. Schinazi]], and Dr. [[Woo-Baeg Choi]] of [[Emory University]] and licensed to[[Triangle Pharmaceuticals]] by Emory in 1996.<ref>{{cite news| url=http://money.cnn.com/magazines/fortune/fortune_archive/2005/09/19/8272884/index.htm| work=CNN | first=Clifton | last=Leaf | title=The Law of Unintended Consequences | date=September 19, 2005}}</ref> Triangle Pharmaceuticals was acquired in 2003 by [[Gilead Sciences]], who completed development and now market the product with the brand name ''Emtriva''. | |||
It was approved by the FDA July 2, 2003. It is very similar to [[lamivudine]] (3TC) and cross-resistance between the two is near-universal.{{Citation needed|date=October 2010}} | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
Revision as of 06:29, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Emtricitabine (FTC), with trade name Emtriva (formerly Coviracil), is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults and children.
Emtricitabine is also marketed in a fixed-dose combination with tenofovir (Viread) under the brand name Truvada. A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006 under the brand name Atripla.
Emtricitabine makes up one fourth of the Quad pill (brand name: Stribild).
Category
Antiretroviral drug
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages
Historical Perspective
Emtricitabine was discovered by Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi, and Dr. Woo-Baeg Choi of Emory University and licensed toTriangle Pharmaceuticals by Emory in 1996.[1] Triangle Pharmaceuticals was acquired in 2003 by Gilead Sciences, who completed development and now market the product with the brand name Emtriva.
It was approved by the FDA July 2, 2003. It is very similar to lamivudine (3TC) and cross-resistance between the two is near-universal.[citation needed]
Mechanism of Action
References
- ↑ Leaf, Clifton (September 19, 2005). "The Law of Unintended Consequences". CNN.